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Bronchopulmonary dysplasia (BPD), cur-
rently the most common chronic respi-
ratory disease in infants, is a multifacto-
rial disease secondary to genetic (1) and
environmental factors (chief among them
being exposure to invasive mechanical ven-
tilation, ante- and postnatal infections,
and hyperoxia) (2, 3). It is estimated that
approximately 10,000–15,000 new cases of
BPD occur each year in the United States,
of which 97% occur in infants with birth
weights <1250 g (3). Over the last decade,
the incidence of BPD has been reported
variably to have decreased (4), remained
the same (5), or even increased slightly
(3, 6, 7). However, there is uniform agree-
ment that BPD is associated with signif-
icant resource utilization and increased
costs (4, 8). While studies assessing the eco-
nomic burden of BPD are mostly restricted
to their initial hospitalization in neona-
tal intensive care units (4, 8), this is a
chronic lung disease with significant pul-
monary and neurodevelopmental seque-
lae (3, 9, 10) that impacts healthcare costs
into the pediatric age group (11, 12) and
would be expected to continue to do so into
adulthood (13).
Given the above data, novel effective
drug therapies for the prevention of BPD
would potentially make a significant dif-
ference in the health and costs for pre-
maturely born children. A recent work-
shop conducted under the auspices of the
National Heart Lung and Blood Institute
of the National Institutes of Health on
the primary prevention of chronic lung
diseases focused on BPD (14). In terms
of “promising near-term opportunities for
primary BPD prevention research,” specif-
ically, “clinical research priorities and spe-
cific clinical trials for BPD prevention,” it
was disappointing to note that only two
specific drugs were named: caffeine and
inhaled nitric oxide (iNO).
While caffeine has been associated with
improvement in BPD (15) and neurodevel-
opmental outcomes (16) [unfortunately,
not sustained at 5 years of age (17)], stud-
ies fine-tuning the timing of initiation and
duration of use of this drug would be
useful. This is important given the fact
that the mechanism of action in terms
of the pulmonary effects in the develop-
ing lung is not currently understood and
toxicity concerns have been raised in an
animal study (18). Despite a large num-
ber of infants being studied in random-
ized clinical trials (RCTs), iNO has not
been consistently found to be beneficial in
preventing BPD and is currently not rec-
ommended for such treatment (19, 20).
It is therefore critical that for both caf-
feine and iNO, given past experience, sub-
group targeted therapy (21) should be
tested in future RCTs. Such targeted sub-
groups could be on the basis of genotype
or phenotype (for e.g., small for gesta-
tional age infants) criteria. Assessment of
genotypes would be a useful technique to
identify specific populations most likely
to benefit from such a targeted approach,
which would incorporate the not insignif-
icant effects of the genetic contribution to
BPD (1, 22–24).
On searching the clinicaltrials.gov data-
base with the terms “drugs” and “BPD”
(accessed on May 15, 2014; including only
“open” studies that are actively recruiting;
excluding those with “unknown status”),
24 studies were identified. Among these,
those with specific drug therapy with
the primary or secondary outcome listed
as assessment of BPD included caffeine
(1 trial), recombinant human Clara Cell
10 kDa protein (1 trial), iNO (2 trials),
macrolide antibiotics (2 trials), hydrocorti-
sone (2 trials), vitamin D (1 trial), remifen-
tanil (1 trial), appropriate levels of oxy-
gen (1 trial), maternal N -acetyl cysteine (1
trial), maternal enoxaparin (1 trial), and
l-thyroxine (1 trial).
While awaiting the results of these
clinical trials over the next few years, it
is important that currently used drugs
(approved for use in non-BPD medical
conditions) be also tested and new drugs
be developed to target novel molecular
targets that have been identified in studies
conducted in animal models of BPD (25).
This becomes especially important since
the incidence of BPD appears to be the
same or slightly increased (25), despite
the continuing use of non-invasive ven-
tilation strategies (26). For translational
impact, molecular targets that have been
identified to be associated with human
BPD would have the maximal potential
to be of clinical use. Such potential thera-
pies include anti-interleukin-1 (anakinra)
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(27), inhibition of Cox-2 and C/EBP
homologous protein (CHOP) (celecoxib)
(28, 29), targeting transforming growth
factor-beta 1 signaling (losartan) (30),
matrix proteins [elastase (elafin) (31),
matrix metalloproteinase-9 (doxycycline)
(28)], augmentation of the parathyroid
hormone-related protein-peroxisome
proliferator-activated receptor-gamma
pathway (rosiglitazone, pioglitazone) (32,
33), modulation of macrophage migration
inhibiting factor (34–36), and chitinase-
3-like protein 1 (37, 38). Appropriate
protocols for testing such drugs and/or
their safer analogs in the preterm newborn
population would need to be developed
and it is imperative that data from studies
conducted in older children and adults
not be interpolated to the neonatal sub-
jects, but independently verified. Strategies
that incorporate drug delivery confined
to the pulmonary compartment would
minimize off-target effects (including
untoward effects) and maximize the thera-
peutic response. For this to occur, given the
current fiscal climate of federal funding,
it is imperative that private philanthropic
foundations with an interest in improving
the health of children as well as pharma-
ceutical companies step up to the plate
to partner with innovative physician-
scientists to support pre-clinical/phase-1
studies of such drug therapies.
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